Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mattson, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mattson, R. H.
NEUROLOGY 1998;51:S15-S20
© 1998 American Academy of Neurology

Medical management of epilepsy in adults

Richard H. Mattson, MD

From the Department of Neurology, Yale University School of Medicine, New Haven, CT.

Address correspondence and reprint requests to Dr. Richard H. Mattson, Department of Neurology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510.

Abstract.

Optimal treatment of epilepsy in adults requires a tailored approach that weighs the efficacy of individual drugs in the specific diagnosis against the patient's risks for adverse events. Partial seizures, which are the most common seizure type in adults, can be effectively controlled by virtually all the standard and newer antiepileptic drugs (AEDs). For the generalized epilepsies, valproate remains the drug of choice. Data continue to accumulate regarding use of the newer agents. Overall, many of the newer AEDs may offer a better tolerability than the standard agents because of more favorable pharmacokinetic characteristics and lack of interactions with drugs other than AEDs. Serious adverse events have been associated with felbamate and lamotrigine, however, and more experience is needed with many of the other newer AEDs to better define their safety profiles. Monotherapy should be the goal when AED treatment is instituted for the adult with epilepsy. Dosage modification on the basis of seizure control and toxicity should be implemented, as well as single-drug trials with alternative AEDs, before resorting to polytherapy. With the introduction of several promising newer AEDs, safe and effective seizure control may become a reality for an increasing number of adults with epilepsy.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.